Acoramidis Slows Health Status Decline in ATTR-CM

This prespecified secondary analysis of ATTRibute-CM quantifies acoramidis's patient-reported health status benefit in transthyretin amyloid cardiomyopathy, complementing its established mortality and hospitalization reductions.

acoramidistafamidisvutrisiranTTR stabilizertransthyretin amyloid cardiomyopathyATTR-CMheart failurepatient-reported outcomesKCCQsecondary analysisrandomized controlled trial Cardiology / Anticoagulation

Background Information

Acoramidis significantly improves quality of life for ATTR-CM patients.

Acoramidis offers a new potential treatment option for improving heart failure-related health outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. Acoramidis showed a significant improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary scores with a least-squares mean difference of 9.9 points compared to placebo at 30 months. These findings highlight acoramidis' impact on patient-reported outcomes, suggesting it may alter disease progression in ATTR-CM. The study is robust, indicating meaningful clinical benefit. Acoramidis substantially improves heart failure health status in ATTR-CM patients, suggesting it modifies disease progression.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Sherrod CF 4th, Fontana M, Gillmore JD, Kastritis E, Mitchell JD, Krejci J, Tauras JM, van der Meer P, Chen C, Falvey H, Siddhanti S, Tamby JF, Fox JC, Cappelli F, Masri A, Garcia-Pavia P, Hanna M, Sperry BW

Citation: Sherrod CF 4th, Fontana M, Gillmore JD, et al. Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial. JAMA cardiology. 2026. doi:10.1001/jamacardio.2026.2413

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →